Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T33583 |
Naldemedine
S-297995,S297995,Naldemedine,S 297995,S297,995,S 297,995,S297,995;Naldemedine,S-297,995 |
||
Naldemedine (S 297995) is a peripheral selective μ-opioid receptor antagonist being developed by Shionogi for the treatment of opioid-induced adverse reactions, including constipation, nausea, and vomiting. They are usually well tolerated, mainly with mil | |||
T70928 |
CB-1158-analog
|
||
CB-1158-analog, also known as Numidargistat-analog and INCB01158-analog, is a potent and orally active arginase inhibitor with IC50=89 nM) . CB-1158 blocked myeloid cell-mediated suppression of T cell proliferation in vitro and reduced tumor growth in multiple mouse models of cancer, as a single agent and in combination with checkpoint blockade, adoptive T cell therapy, adoptive NK cell therapy, and the chemotherapy agent gemcitabine. CB-1158 increased tumor-infiltrating CD8+ T cells and NK cell... | |||
T70929 |
Naldemedine tosylate
S-297995 tosylate |
||
Naldemedine tosylate (S-297995)为具口服活性的μ-阿片受体拮抗剂(PAMORA)。其对重组人源μ-、δ-及κ-阿片受体展现出高亲和力(Ki分别为0.34,0.43,0.94 nM)及强拮抗效果(IC50分别为25.57,7.09,16.1 nM)。适用于研究由阿片类物质引起的便秘(OIC)。Naldemedine tosylate也被预测可能与SARS-CoV2 3CLpro结合。 |